{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mendias CL"],"funding":["NIAMS NIH HHS"],"pagination":["1916-1928"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7351248"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(8)"],"pubmed_abstract":["<h4>Background</h4>Anterior cruciate ligament (ACL) tears are common knee injuries. Despite undergoing extensive rehabilitation after ACL reconstruction (ACLR), many patients have persistent quadriceps muscle weakness that limits their successful return to play and are also at an increased risk of developing knee osteoarthritis (OA). Human growth hormone (HGH) has been shown to prevent muscle atrophy and weakness in various models of disuse and disease but has not been evaluated in patients undergoing ACLR.<h4>Hypothesis</h4>Compared with placebo treatment, a 6-week perioperative treatment course of HGH would protect against muscle atrophy and weakness in patients undergoing ACLR.<h4>Study design</h4>Randomized controlled trial; Level of evidence, 2.<h4>Methods</h4>A total of 19 male patie"],"journal":["The American journal of sports medicine"],"pubmed_title":["The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial."],"pmcid":["PMC7351248"],"funding_grant_id":["F31 AR065931"],"pubmed_authors":["Enselman ERS","Mendias CL","Jacobson JA","Olszewski AM","Konnaris MA","Bedi A","Gagnier JJ","Awan TM","Barkan AL","Gumucio JP","Edon DL","Carpenter JE"],"additional_accession":[]},"is_claimable":false,"name":"The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.","description":"<h4>Background</h4>Anterior cruciate ligament (ACL) tears are common knee injuries. Despite undergoing extensive rehabilitation after ACL reconstruction (ACLR), many patients have persistent quadriceps muscle weakness that limits their successful return to play and are also at an increased risk of developing knee osteoarthritis (OA). Human growth hormone (HGH) has been shown to prevent muscle atrophy and weakness in various models of disuse and disease but has not been evaluated in patients undergoing ACLR.<h4>Hypothesis</h4>Compared with placebo treatment, a 6-week perioperative treatment course of HGH would protect against muscle atrophy and weakness in patients undergoing ACLR.<h4>Study design</h4>Randomized controlled trial; Level of evidence, 2.<h4>Methods</h4>A total of 19 male patie","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-20T01:11:09.19Z","creation":"2022-02-10T17:24:34.325Z"},"accession":"S-EPMC7351248","cross_references":{"pubmed":["32452208"],"doi":["10.1177/0363546520920591"]}}